Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1992 Feb;75(2):343-8.

Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes

Affiliations

Evidence that interleukin-4 suppression of lymphokine-activated killer cell induction is mediated through monocytes

B Brooks et al. Immunology. 1992 Feb.

Abstract

Recombinant human interleukin-4 (IL-4) and transforming growth factor-beta (TGF-beta) reduce recombinant interleukin-2 (IL-2) induction of lymphokine-activated killer (LAK) cell activity from human peripheral blood mononuclear cells (PBMC). Monocytes can be removed from PBMC by adherence, leaving a peripheral blood lymphocyte population (PBL) which also responds to IL-2 to generate LAK activity. PBL generation of LAK cytotoxicity is susceptible to inhibition by TGF-beta, but not by IL-4. Readdition of purified monocytes to PBL is accompanied by return of the suppressive action of IL-4 on the generation of LAK activity. Induction of LAK cytolysis from Percoll-isolated T cells (greater than 90% CD3+) is also refractory to the inhibitory effect of IL-4. When PBMC were cultured in IL-2, with and without IL-4, subsequent sorting of CD3+ and CD3- lymphocytes by flow cytometry demonstrated that IL-4 had suppressed LAK induction in both effector populations. This suggests that, although isolated CD3+ cells are not susceptible to IL-4 suppression of IL-2 activation, they are sensitive to inhibition when part of a mixed PBMC population. Evidence is presented for the first time that this suppression is mediated via the action of IL-4 on monocytes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cancer Res. 1976 Dec;36(12):4562-9 - PubMed
    1. J Exp Med. 1982 Jun 1;155(6):1823-41 - PubMed
    1. Cell Immunol. 1990 Jul;128(2):450-61 - PubMed
    1. Lymphokine Res. 1990 Fall;9(3):283-93 - PubMed
    1. J Immunol. 1990 Sep 1;145(5):1435-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources